LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Read More…
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Phone44-0-20-3325-0660
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.11 billion
Profitability
Miscellaneous
Employees4,000
Next Earnings Date10/30/2019 (Confirmed)
OptionableOptionable
LivaNova (NASDAQ:LIVN) Frequently Asked Questions
What is LivaNova's stock symbol?
LivaNova trades on the NASDAQ under the ticker symbol "LIVN."
How were LivaNova's earnings last quarter?
LivaNova PLC (NASDAQ:LIVN) announced its quarterly earnings data on Wednesday, July, 31st. The company reported $0.56 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.59 by $0.03. The company had revenue of $277.20 million for the quarter, compared to the consensus estimate of $275.14 million. LivaNova had a negative net margin of 23.86% and a positive return on equity of 8.56%. The company's revenue was down 3.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.96 earnings per share. View LivaNova's Earnings History.
When is LivaNova's next earnings date?
How can I listen to LivaNova's earnings call?
LivaNova will be holding an earnings conference call on Wednesday, October 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has LivaNova issued on next quarter's earnings?
LivaNova issued an update on its FY19 earnings guidance on Wednesday, July, 31st. The company provided EPS guidance of $3.00-3.10 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.03. The company issued revenue guidance of +1-3% yr/yr to $1.2-1.4 billion, compared to the consensus revenue estimate of $1.11 billion.
What price target have analysts set for LIVN?
6 equities research analysts have issued 12 month target prices for LivaNova's shares. Their forecasts range from $90.00 to $114.00. On average, they expect LivaNova's stock price to reach $100.00 in the next twelve months. This suggests a possible upside of 34.8% from the stock's current price. View Analyst Price Targets for LivaNova.
What is the consensus analysts' recommendation for LivaNova?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for LivaNova.
What are Wall Street analysts saying about LivaNova stock?
Here are some recent quotes from research analysts about LivaNova stock:
- 1. According to Zacks Investment Research, "LivaNova PLC is a medical technology company which focuses on providing treatment for cardiovascular diseases and neuromodulation. The Company's operating units consists of Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation. LivaNova PLC, formerly known as Cyberonics, Inc., is based in London, United Kingdom. " (10/2/2019)
- 2. BTIG Research analysts commented, "As expected, LIVN revised down FY19 guidance following the pre- announcement. Although we had taken down estimates following the miss, the cut to the U.S. Neuromod outlook was still $10-20M worse than we expected. FY19 EPS is now expected to reach $3.00-3.10, ~$0.15 lower than our already lowered $3.21 forecast. Comps turn more difficult on the base business but with a fuller impact from Epidiolex going forward and no imminent relief in the lagging Heart valves business, we feel that even meeting the low end of the 1-3% constant currency guidance could prove challenging. Optics should improve in the back half when the TRD trial begins to enroll but even successful enrollment and reimbursement are not entirely certain. Overall, we think it will take a few quarters to regain credibility and enhance investor confidence in a turnaround in FY20." (5/2/2019)
- 3. Needham & Company LLC analysts commented, "LIVN beat consensus revenue and EPS in 4Q18. Management provided 2019 revenue growth guidance that was above consensus at the mid-point and adjusted EPS guidance that was below consensus due to treatment- resistant depression (TRD) investments (costing $0.15-0.20 of EPS). Organic revenue growth slowed to 7% in 4Q18 from 8% in 3Q18 given a tougher comp and weakness in Cardiovascular, slightly offset by strength in Neuromodulation. Gross margin was up 470 bps Y/Y while operating margin was up 80 bps Y/Y due to SG&A and R&D investments to fund current and future growth initiatives. While we expect LIVN’s reinvestment to weigh on its margins and EPS in the near-term, we believe it will drive faster revenue growth in future periods and we reiterate our Buy rating." (2/27/2019)
Has LivaNova been receiving favorable news coverage?
Headlines about LIVN stock have been trending somewhat positive on Wednesday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. LivaNova earned a coverage optimism score of 0.6 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for LivaNova.
Are investors shorting LivaNova?
LivaNova saw a decrease in short interest in September. As of September 30th, there was short interest totalling 1,860,000 shares, a decrease of 7.5% from the August 30th total of 2,010,000 shares. Based on an average daily trading volume, of 392,400 shares, the days-to-cover ratio is currently 4.7 days. Approximately 3.9% of the shares of the stock are short sold. View LivaNova's Current Options Chain.
Who are some of LivaNova's key competitors?
Some companies that are related to LivaNova include SONOVA HLDG AG/ADR (SONVY), Varian Medical Systems (VAR), Masimo (MASI), GETINGE AB/ADR (GNGBY), CONMED (CNMD), Natus Medical (NTUS), Natus Medical (BABY), InMode (INMD), AxoGen (AXGN), Cutera (CUTR), TransMedics Group (TMDX), BioLife Solutions (BLFS), Zynex (ZYXI), Semler Scientific (SMLR) and Viewray (VRAY).
What other stocks do shareholders of LivaNova own?
Who are LivaNova's key executives?
LivaNova's management team includes the folowing people:
- Mr. Damien McDonald, CEO & Director (Age 54)
- Mr. Thad Huston, Chief Financial Officer (Age 49)
- Mr. Douglas J. Manko, Chief Accounting Officer (Age 45)
- Ms. Keyna Pidcock Skeffington, Gen. Counsel & Sr. VP (Age 56)
- Mr. David S. Wise, Sr. Advisor (Age 64)
Who are LivaNova's major shareholders?
LivaNova's stock is owned by a number of of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.25%), CWM LLC (0.16%), Strs Ohio (0.04%), State of Michigan Retirement System (0.03%), Envestnet Asset Management Inc. (0.03%) and Virginia Retirement Systems ET AL (0.02%). Company insiders that own LivaNova stock include Alfred J Novak, Alistair Simpson, Damien Mcdonald, Daniel Jeffrey Moore, David S Wise, Douglas John Manko, Francesco Bianchi, Hugh M Morrison, Thad Allen Huston and William A Kozy. View Institutional Ownership Trends for LivaNova.
Which institutional investors are selling LivaNova stock?
LIVN stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Zurcher Kantonalbank Zurich Cantonalbank , Strs Ohio, State of Michigan Retirement System, Crossmark Global Holdings Inc. and Financial Gravity Wealth Inc.. Company insiders that have sold LivaNova company stock in the last year include Alfred J Novak, Alistair Simpson, Damien Mcdonald, Daniel Jeffrey Moore, David S Wise, Hugh M Morrison and Thad Allen Huston. View Insider Buying and Selling for LivaNova.
Which institutional investors are buying LivaNova stock?
LIVN stock was bought by a variety of institutional investors in the last quarter, including CWM LLC, Virginia Retirement Systems ET AL, State of Alaska Department of Revenue, Henry James International Management Inc., Fox Run Management L.L.C., Nisa Investment Advisors LLC, Envestnet Asset Management Inc. and Cerebellum GP LLC. View Insider Buying and Selling for LivaNova.
How do I buy shares of LivaNova?
Shares of LIVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is LivaNova's stock price today?
One share of LIVN stock can currently be purchased for approximately $74.20.
How big of a company is LivaNova?
LivaNova has a market capitalization of $3.59 billion and generates $1.11 billion in revenue each year. The company earns $-189,400,000.00 in net income (profit) each year or $3.17 on an earnings per share basis. LivaNova employs 4,000 workers across the globe.View Additional Information About LivaNova.
What is LivaNova's official website?
How can I contact LivaNova?
LivaNova's mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The company can be reached via phone at 44-0-20-3325-0660 or via email at [email protected]
MarketBeat Community Rating for LivaNova (NASDAQ LIVN)
MarketBeat's community ratings are surveys of what our community members think about LivaNova and other stocks. Vote "Outperform" if you believe LIVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LIVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
